452339-73-0

Basic information

• Product Name: 2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-, (5R)-
• Synonyms: 2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-, (5R)-;(5R)-2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl);(5R)-5-(2,2-DiMethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one;(R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one
• CAS NO: 452339-73-0
• Molecular Formula: C₁₃H₁₅NO₄
• Molecular Weight: 249.2625
• EINECS: 1592732-453-0
• Product Categories: Intermediate
• Mol File: 452339-73-0.mol

Chemical Properties

• Boiling Point: 489.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.223±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• Solubility: Chloroform (Sparingly), Methanol (Slightly)
• PKA: 12.29±0.40(Predicted)
• CAS DataBase Reference: 2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-, (5R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-, (5R)-(452339-73-0)
• EPA Substance Registry System: 2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-, (5R)-(452339-73-0)

Safety Data

• Hazardous Substances Data: 452339-73-0(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 452339-73-0 differently. You can refer to the following data:
1. (5R)-5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-2-Oxazolidinone is a reagent applied in the preparation of alkyl-linked di-phenyl aminoalcohols as long-acting β2 adrenergic receptor agonist. It is used as an antedrug.
2. R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one is a reagent applied in the preparation of alkyl-linked di-phenyl aminoalcohols as long-acting β2 adrenergic receptor agonist. An antedrug.

Upstream product

• 102293-80-1 2-bromo-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethanone 
• 208925-08-0 (2R)-hydroxy-2-(2,2-dimethyl-4H-1,3-benzodioxine-6-yl)-ethylamine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 1761-61-1 5-bromosalicyclaldehyde 
• 2316-64-5 5-bromo-2-hydroxybenzyl alcohol 
• 52113-69-6 6-bromo-2,2-dimethyl-4H-benzo[1,3]dioxine 
• 54030-34-1 1-(2,2-dimethyl-4H-benzo[d][1,3]dioxan-6-yl)ethanone 
• 452339-71-8 tert-butyl 2-(2,2-dimethyl-4H-1,3-benzodioxane-6-yl)-2-carbonylethylcarbamate 
• 452339-72-9 tert-butyl (2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethylcarbamate 
• 452339-70-7 di-(tert-butyl) 2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxoethyliminodicarbonate 

Downstream Products

• 590410-68-7 (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-[6-(4-phenylbutoxy)hexyl]-1,3-oxazolidin-2-one 
• 135271-47-5 (R)-(-)-salmeterol 
• 590410-69-8 (R)-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)-2-(6-(4-phenylbutoxy)hexylamino)ethanol 
• 671777-40-5 (5R)-5-(2, 2-DIMETHVL-4H-1, 3-BENZODIOXIN-6-VL)-3-F₆-R₄-(3-IODOPHENVL) BUTOXVLHEXVL-1, 3-oxazolidin-2-one 
• 503068-33-5 (5R)-3-(6-bromohexyl)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one 
• 686734-43-0 (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-{6-[(4-methyl-4-phenylpentyl)oxy]hexyl}-1,3-oxazolidin-2-one 
• 686351-12-2 (5R)-3-[6-(3-buten-1-yloxy)hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one 
• 452340-53-3 (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-[6-(4-pentyn-1-yloxy)hexyl]-1,3-oxazolidin-2-one 
• 452339-74-1 (5R)-3-[6-(3-butyn-1-yloxy)-hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one 
• 688798-46-1 (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-{6-[4-(4-iodophenyl)butoxy]hexyl}-1,3-oxazolidin-2-one 
• 620600-85-3 (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-{2-[4-(4-phenylbutoxy)phenyl]ethyl}-1,3-oxazolidin-2-one 
• 620600-21-7 (5R)-3-(2-{2-[2-(benzyloxy)ethoxy]phenyl}ethyl)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one 
• 620600-00-2 2-(4-{2-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]ethyl}phenoxy)ethyl acetate 
• 452340-27-1 (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-[5-(pent-4-ynyloxy)pentyl]-1,3-oxazolidin-2-one 

Relevant articles and documents

Phenylethanolamine derivative and its preparation method and application

The invention relates to a phenylethanolamine derivative represented in the following formula 1. The phenylethanolamine derivative can serve as a beta 2 receptor agonist. The formula can be seen from the description.

Preparation method and application of polyoxometalate crystal

The invention belongs to the technical field of organocatalysis and in particular relates to a preparation method and application of a polyoxometalate crystal. The preparation method disclosed by the invention comprises the following steps: by taking Na2WO4.2H2O, NaVO3.2H2O, disodium hydrogen phosphate, manganese acetate and benzyl tri-n-butylammonium chloride as raw materials, preparing the heteropolyacid crystal. Catalyzed preparation of an anti-asthma drug vilanterol trifenatate intermediate is realized by taking the polyoxometalate crystal as a catalyst. The defect in the conventional process that a strong base is adopted is overcome, the pressure for environmental protection is alleviated, the process route is green and environment-friendly, and the requirements on the conventional industrial production are met.

PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF

An improved process for the preparation of vilanterol and pharmaceutically acceptable salts thereof is disclosed. More specifically the improved process for preparing intermediates for the preparation of vilanterol is disclosed.

DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR

The present invention provides a compound of formula (I) wherein: R1 is a group selected from -CH2OH, -NHC(O)H and R2 is a hydrogen atom; or R1 together with R2 form the group -NH-C(O)-CH=CH- wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R1 and the carbon atom is bound to the carbon atom in the phenyl ring holding R2; R3 is selected from hydrogen and halogen atoms or groups selected from -SO-R5, -SO2- R5, -NH-CO-NH2, -CO-NH2, hydantoino, C1-4alkyl, C1-4alkoxy and -SO2NR5R6; R4 is selected from hydrogen atoms, halogen atoms and C1-4alkyl groups; R5 is a C1-4alkyl group or C3-8 cycloalkyl; R6 is independently selected from hydrogen atoms and C1-4alkyl groups; n, p and q are independently 0, 1 , 2, 3 or 4; m and s are independently 0, 1 , 2 or 3; r is 0, 1 or 2; with the provisos that: at least one of m and r is not 0; the sum n+m+p+q+r+s is 7, 8, 9, 10, 11 , 12 or 13; the sum q+r+s is 2, 3, 4, 5 or 6 or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof.

PHENETHANOLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES

The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES

The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

Potassium trimethylsilanolate induced cleavage of 1,3-oxazolidin-2- and 5-ones, and application to the synthesis of (R)-salmeterol.

A convenient and efficient method for the cleavage of 1,3-oxazolidin-5-ones and 1,3-oxazolidin-2-ones utilising potassium trimethylsilanolate in tetrahydrofuran is described. The benzyloxycarbonyl-protecting group is readily removed under the reaction conditions, whereas the N-benzoyl group is stable. A synthesis of (R)-salmeterol exploiting the 2-oxazolidinone ring as a protecting group for the ethanolamine moiety is also described.

PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES

The present invention relates to novel compounds of formula (I),to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

PHENETHANOLAMINE DERIVATIVES

The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.